ADMA Biologics (NASDAQ:ADMA) saw its stock price plummet 10.73% in after-hours trading on Wednesday following the release of its second-quarter financial results. The biopharmaceutical company's earnings met expectations, but sales fell short of analyst estimates, triggering the sharp decline.
ADMA reported quarterly earnings of $0.14 per share, in line with analyst consensus estimates and representing a 7.69% increase from the same period last year. However, the company's quarterly sales of $121.98 million missed the analyst consensus estimate of $122.67 million by 0.56%. Despite the miss, this still marks a 13.80% increase over sales of $107.19 million in the same period last year.
While ADMA Biologics reaffirmed its fiscal year 2025-2026 guidance for total revenue, adjusted EBITDA, and adjusted net income, investors appear to be focusing on the sales miss. The significant after-hours drop suggests that market participants may have been expecting stronger results or were disappointed by the company's performance relative to expectations, despite the year-over-year growth. The reaction highlights the market's sensitivity to even slight misses in revenue projections, particularly for growth-oriented biopharmaceutical companies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.